Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Short term Debt (2022 - 2024)

Roivant Sciences (ROIV) has disclosed Short term Debt for 3 consecutive years, with $12.0 million as the latest value for Q2 2024.

  • For the quarter ending Q2 2024, Short term Debt fell 72.98% year-over-year to $12.0 million, compared with a TTM value of $12.0 million through Jun 2024, down 72.98%, and an annual FY2024 reading of $12.0 million, down 70.53% over the prior year.
  • Short term Debt was $12.0 million for Q2 2024 at Roivant Sciences, roughly flat from $12.0 million in the prior quarter.
  • Across five years, Short term Debt topped out at $49.0 million in Q3 2023 and bottomed at $12.0 million in Q1 2024.
  • Average Short term Debt over 3 years is $34.5 million, with a median of $37.7 million recorded in 2022.
  • The sharpest move saw Short term Debt soared 37.04% in 2023, then tumbled 72.98% in 2024.
  • Year by year, Short term Debt stood at $37.7 million in 2022, then increased by 21.16% to $45.7 million in 2023, then crashed by 73.75% to $12.0 million in 2024.
  • Business Quant data shows Short term Debt for ROIV at $12.0 million in Q2 2024, $12.0 million in Q1 2024, and $45.7 million in Q4 2023.